ALNT vs ARRY

Allient Inc. (ALNT) exhibits a Piotroski F-Score of 4, indicating a stable but not strong financial health, with no Altman Z-Score available to assess bankruptcy risk. The stock trades at a premium to its Graham Number ($21.18) and intrinsic value ($33.04), reflecting strong growth expectations rather than undervaluation. Despite elevated valuation metrics—P/E of 55.66 and forward P/E of 20.19—earnings and revenue growth are robust, with YoY earnings up 110.1% and revenue up 17.5%. Insider selling in the last six months and a bearish technical trend temper the outlook, but consistent earnings beats and a strong analyst buy consensus support upside potential. Price trades at a 88.7% premium to fair value estimate ($33.04), limiting near-term upside from a valuation perspective.

ARRY's deterministic health scores signal significant distress: the Piotroski F-Score of 2/9 indicates poor financial health, with weak profitability, declining revenue, and high leverage. The absence of an Altman Z-Score raises concern, as the Debt/Equity ratio of 2.94 and negative ROE (-19.02%) suggest elevated bankruptcy risk. Despite a modest Price/Sales of 0.82 and a forward P/E of 7.86, the company's -17.9% YoY revenue decline and negative profit margins undermine valuation appeal. Analysts recommend 'buy' with a $10.07 target, but this optimism appears disconnected from deteriorating fundamentals. The 52-week price range ($3.76–$12.23) and recent 1M drop of 37.6% reflect high volatility and weak market confidence.